Tirzepatide Once Weekly for the Treatment of Obesity
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obesity is a chronic disease that results in substantial global morbidity and mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, in people with obesity are not known. METHODS: In this phase 3 double-blind, randomized, controlled trial, we assigned 2539 adults with a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, in a 1:1:1:1 ratio to receive once-weekly, subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, including a 20-week dose-escalation period. Coprimary end points were the percentage change in weight from baseline and a weight reduction of 5% or more. The treatment-regimen estimand assessed effects regardless of treatment discontinuation in the intention-to-treat population. RESULTS: At baseline, the mean body weight was 104.8 kg, the mean BMI was 38.0, and 94.5% of participants had a BMI of 30 or higher. The mean percentage change in weight at week 72 was -15.0% (95% confidence interval [CI], -15.9 to -14.2) with 5-mg weekly doses of tirzepatide, -19.5% (95% CI, -20.4 to -18.5) with 10-mg doses, and -20.9% (95% CI, -21.8 to -19.9) with 15-mg doses and -3.1% (95% CI, -4.3 to -1.9) with placebo (P<0.001 for all comparisons with placebo). The percentage of participants who had weight reduction of 5% or more was 85% (95% CI, 82 to 89), 89% (95% CI, 86 to 92), and 91% (95% CI, 88 to 94) with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and 35% (95% CI, 30 to 39) with placebo; 50% (95% CI, 46 to 54) and 57% (95% CI, 53 to 61) of participants in the 10-mg and 15-mg groups had a reduction in body weight of 20% or more, as compared with 3% (95% CI, 1 to 5) in the placebo group (P<0.001 for all comparisons with placebo). Improvements in all prespecified cardiometabolic measures were observed with tirzepatide. The most common adverse events with tirzepatide were gastrointestinal, and most were mild to moderate in severity, occurring primarily during dose escalation. Adverse events caused treatment discontinuation in 4.3%, 7.1%, 6.2%, and 2.6% of participants receiving 5-mg, 10-mg, and 15-mg tirzepatide doses and placebo, respectively. CONCLUSIONS: In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight. (Supported by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, NCT04184622.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Many patients treated with GLP-1RAs achieve clinically meaningful weight loss while simultaneously demonstrating improvements in cardiometabolic health.45,46”
From Receipt of Glucagon-Like Peptide-1 Receptor Agonists Among Rural Patients with Obstructive Sleep Apnea and Excess Weight (2026) · cites this paper as [46]
In the citing paper
“with two articles presenting LM outcomes in only a subset of participants from the parent trial (6, 7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Indeed, clinical trials demonstrate substantial weight loss achievable with GLP1Ra-based therapy, ranging from 12-15% over a one-year period for semaglutide (6), to weight losses rivaling what is seen with bariatric surgery for tirzepatide (7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Across body weight and composition outcomes, the greatest magnitude of weight loss was observed in the SURMOUNT (7) and STEP (6) trials, respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“However, the magnitude of the treatment effect on total body mass was nearly two times greater in trials using GLP1Ra-based therapies at dosages indicated primarily for chronic weight management (6, 7, 18, 21, 24) as compared to trials using dosages indicated primarily for diabetes management (17, 19, 20, 22): −10.2 kg (−16.3, −3.9) versus −5.5 kg (−8.7, −2.1), respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
174 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationObesity and cardiovascular disease: a scientific statement from the American Heart Association
Powell-Wiley, T. M., Poirier, P., Burke, L. E., Després, J.-P., Gordon-Larsen, P., Lavie, C. J., Lear, S. A., Ndumele, C. E., Neeland, I. J., Sanders, P., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000973 · Cited by 3,691
Di Angelantonio, E., Bhupathiraju, S. N., Wormser, D., Gao, P., Kaptoge, S., de Gonzalez, A. B., Cairns, B. J., Huxley, R., Jackson, C. L., Joshy, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30175-1 · Cited by 2,821
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
2. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s002 · Cited by 2,697
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Self-citationGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Self-citationObesity in adults: a clinical practice guideline
Wharton, S., Lau, D. C. W., Vallis, M., Sharma, A. M., Biertho, L., Campbell-Scherer, D., Adamo, K., Alberga, A., Bell, R., Boulé, N., et al. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.191707 · Cited by 1,506
Self-citationRubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Cited by
Items 2,101–2,200 of 3,704
Ray, S., Kapoor, N., Deshpande, N., Chatterjee, S., Kumar, J. S., Tantia, O., Goyal, G., Mukherjee, J. J., & Singh, A. K. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2330468 · Cited by 3
“Initially, the drug was tested for the management of T2DM in a series of clinical trials called the SURPASS trials [81], but more recently, three specific anti-obesity phase III trials have been published, which are named SURMOUNT 1, SURMOUNT 2, and SURMOUNT 3 [82–84].”
BackgroundMethodA New Epoch in Treating Diseases of the Heart
Purnell, J. Q., & Camacho, S. A. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.01.007 · Cited by 2
IMPROVE 2022 International Meeting on Pathway‐Related Obesity : Vision of Excellence
Kühnen, P., Argente, J., Clément, K., Dollfus, H., Dubern, B., Farooqi, I. S., de Groot, C., Grüters, A., Holm, J., Hopkins, M., et al. (2024) · Clinical Obesity · doi:10.1111/cob.12659 · Cited by 2
Long-Circulating Vasoactive 1,18-Octadecanedioic Acid–Terlipressin Conjugate
Berger, O., Choi, W., Ko, C. H., Thompson, M. P., Avram, M. J., Scott, D. J., Hoare, B. L., Cridge, R. R., Wheatley, M., Bathgate, R. A. D., et al. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.3c00305 · Cited by 2
An Overview of Modern Strategies for Treating Obesity
Jędrasek, A., Barg, M., Biały-Karbowniczek, J., Bartela, A., & Wojtyła, K. (2024) · Journal of Education Health and Sport · doi:10.12775/jehs.2024.68.49506 · Cited by 2
Doryń, A., Woźniak, K., Jung, M., Jung, M., Hedesz, P., Warzycka, K., Gardian-Baj, M., Szczerbiak, A., Ulicka, W., Kuśmierczyk, K., et al. (2024) · Journal of Education Health and Sport · doi:10.12775/jehs.2024.71.49544 · Cited by 3
The complex web of obesity: from genetics to precision medicine
Nair, J. M., & Bharadwaj, D. (2024) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2024.2365785 · Cited by 3
“…for 72 weeks resulted in 22.5% weight loss in non-diabetic individuals and a loss of 15.7% in diabetic individuals along with a reduction in HbA1c [123,124]. c. Poly-incretin agonist – Recently, poly-agonists with the combination of GIP, glucagon receptor (GcgR), and GLP1R are emerging to be…”
InfluentialHornick, M. A., Chao, G. F., Ying, L., Nadzam, G. S., Duffy, A. J., Ghiassi, S., Graetz, E., Gibbs, K. E., & Morton, J. M. (2024) · Obesity Surgery · doi:10.1007/s11695-024-07374-3 · Cited by 2
“A better understanding of the distribution of long-term weight loss outcomes after LSG in young patients is particularly important in our current era of increasingly effective anti-obesity medications available as primary or adjunct therapy [17–19].”
GLP-1/GIP Receptor Agonists: Mechanism of Action of Tirzepatide
Oh, T. J. (2024) · Journal of Korean Diabetes · doi:10.4093/jkd.2024.25.2.76 · Cited by 2
Versorgungskonzepte für Kinder und Jugendliche mit extremer und/oder genetischer Adipositas
Zorn, S., Schirmer, M., von Schnurbein, J., Brandt, S., Göpel, E., Stein, R., Wiegand, S., Körner, A., Kühnen, P., & Wabitsch, M. (2024) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-2292-1830 · Cited by 3
Pharmacotherapy of obesity: State of the art and perspectives
Sićović, K., & Micov, A. M. (2024) · Arhiv za farmaciju · doi:10.5937/arhfarm74-50625 · Cited by 3
Health gains from achieving optimal body mass index in Australia: a simulation study
Bohora, S., Mishra, S. R., Wilson, T. E., & Blakely, T. A. (2024) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2024.101148 · Cited by 3
“Put another way, an important added value of our study is that it simulates what we think the likely actual health gains would be in the future from changing body weight now — and lays the foundation for determining which actual interventions achieve much of this health gain (examples of potential interventions includ…”
BackgroundIncretin-mediated control of cardiac energy metabolism
Chan, J. S. F., Shafaati, T., & Ussher, J. R. (2024) · Journal of Endocrinology · doi:10.1530/joe-24-0011 · Cited by 2
Understanding the interplay between chronic lymphocytic leukemia and type 2 diabetes
Vainer, N., Curovic, V. R., Niemann, C. U., Slager, S. L., & Rotbain, E. C. (2024) · Expert Review of Hematology · doi:10.1080/17474086.2024.2383417 · Cited by 4
“Furthermore, non-steroidal mineralocorticoid receptors have shown additive cardiorenal protection in T2D [27,28], and novel dual-and triple-agonists are exhibiting weight loss and improved metabolic function on par with those seen after bariatric surgery [29–32].”
GLP-1 RAs: The newest powerhouse in metabolic medicine
Drake, E. S., Marino, A. B., Theroux, J. D., & Roberts, K. (2024) · The Nurse Practitioner · doi:10.1097/01.npr.0000000000000216 · Cited by 2
Are the lipid-lowering effects of incretin-based therapies relevant for cardiovascular benefit?
Alnima, T., Smits, M. M., & Hanssen, N. M. J. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000949 · Cited by 3
The Patient’s Journey in Obesity within the United States: An Exercise of Resilience against Disease
Northam, K. A., Hinds, M., Bodepudi, S., & Stanford, F. C. (2024) · Life · doi:10.3390/life14091073 · Cited by 4
“With tirzepatide (Zepbound), this is 3–6% [47].”
Obesity in Heart Failure with Reduced Ejection Fraction
Amdahl, M. B., Sundaram, V., & Reddy, Y. N. V. (2024) · Heart Failure Clinics · doi:10.1016/j.hfc.2024.06.006 · Cited by 3
Cardiovascular disease risk in people of African ancestry with HIV in the United Kingdom
Ko, S., Domínguez, L., Ottaway, Z. V., Campbell, L. J., Fox, J. M., Burns, F. M., Hamzah, L., Ustianowski, A., Clarke, A. E., Kegg, S., et al. (2024) · HIV Medicine · doi:10.1111/hiv.13706 · Cited by 1
Talay, L., & Vickers, M. (2024) · Pharmacy · doi:10.3390/pharmacy12050135 · Cited by 5
“Additionally, clinical trials have consistently found GLP-1 RAs to be safe and highly effective in weight-loss cohorts [17,18].”
BackgroundTratamiento farmacológico de la obesidad. Situación actual y nuevos tratamientos
Pérez, J. S., & Miguel, G. A. (2024) · Atención Primaria · doi:10.1016/j.aprim.2024.103074 · Cited by 9
Charting New Territories in Obesity Management- Traditional Techniques to Tirzepatide
Fareed, A., Ghanem, L., Vaid, R., Iftikhar, Z., Rehman, A. U., Sarwar, A., & Asif, M. I. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.09.004 · Cited by 4
Kukova, L., Munir, K. M., Sayeed, A., & Davis, S. N. (2024) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2024.2401589 · Cited by 3
“%] lose ≥ 5% body weight; approximately 70–80% of individuals lose ≥ 10% body weight, and approximately 32% sema-glutide-treated and 56% tirzepatide-treated individuals lose ≥ 20% body weight when given higher doses for over a year [26,29].”
Talay, L., & Vickers, M. (2024) · Obesities · doi:10.3390/obesities4040032 · Cited by 3
Bariatric and endo-bariatric interventions for diabetes: What is the current evidence?
Mondal, S., Fistus, V. A., & Pappachan, J. M. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i11.2255 · Cited by 2
Talay, L., Vickers, M., Bell, C., & Galvin, T. (2024) · Telemedicine Reports · doi:10.1089/tmr.2024.0058 · Cited by 5
Are GLP-1 drugs really for everybody?
(2024) · Nature Medicine · doi:10.1038/s41591-024-03382-z · Cited by 3
Kamarullah, W., Pranata, R., Wiramihardja, S., & Tiksnadi, B. B. (2024) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00695-9 · Cited by 3
“…without T2DM have yet to be demonstrated, due to the fact that there was insufficient statistical power in none of the studies to provide a valid assessment of the drugs’ influence on MACE’s risk reduction, and some, but not all, trials showed supremacy over placebo in the sense of MACE [12–15].”
Glucagon-like peptide-1 receptor
Krashes, M. J. (2024) · Current Biology · doi:10.1016/j.cub.2024.10.039 · Cited by 2
Kaye, A. D., Lien, N., Vuong, C. A., Schmitt, M. H., Soorya, Y., Abubakar, B. A., Muiznieks, L., Embry, N. J., Siddaiah, H. B., Kaye, A. M., et al. (2024) · Cureus · doi:10.7759/cureus.76101 · Cited by 6
Bile acids and incretins as modulators of obesity-associated atherosclerosis
Kirsch, A., Gindlhuber, J., Zabini, D., & Osto, E. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1510148 · Cited by 3
Chien, T.-E., Chen, P., Chang, K., Hsu, C., Huang, H.-W., Tsai, S., Chen, Y., Chang, C.-H., Yang, H.-R., Tung, Y., et al. (2024) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2025.01.001 · Cited by 2
Leite, A. R., Dias, J., Godinho, T., Correia-Chaves, J., Borges‐Canha, M., Lourenço, I. M., Leite-Moreira, A. F., & Neves, J. S. (2024) · Endocrinology Insights · doi:10.1159/000541442 · Cited by 5
“All these drugs have been shown to induce substantial weight reduction in placebo-controlled trials involving persons with type 2 diabetes mellitus and/or obesity [123 – 126].”
Siwiec, J., Śpiołek, O., Wąsowicz, A. A., Sztyler-Krąkowska, M. P., Teofilak, M., Smyl, N., Słowikowska, A., Szatkowska, J., Kędziora, F., & Fabian, D. (2025) · Journal of Education Health and Sport · doi:10.12775/jehs.2025.77.56962 · Cited by 3
“Additionally, tirzepatide was associated with substantial reductions in waist circumference and improvements in various cardiometabolic risk factors, including blood pressure and lipid levels 38,39 .”
InfluentialToward a New SUMMIT in Heart Failure with Preserved Ejection Fraction
Felker, G. M. (2025) · New England Journal of Medicine · doi:10.1056/nejme2415551 · Cited by 2
Treatment of obesity in spinal cord injury with tirzepatide: a case report
Juszczak, M., & Shem, K. L. (2025) · Spinal Cord Series and Cases · doi:10.1038/s41394-025-00699-w · Cited by 2
“Previous studies in the general population have noted improvements in waist circumference, blood pressure, fasting insulin levels, lipid levels, and the ratio of total fat mass to lean fat mass in those receiving tirzepatide to assist with weight loss [34].”
Bariatric Medicine: A Comparative Review of Current Trends in Obesity Management
Onyebuchi, C., Uzochukwu-Obi, O., & Jeremiah, C. S. (2024) · medtigo Journal of Medicine · doi:10.63096/medtigo3062250 · Cited by 2
Great Weight, Low Pressure–One Problem: GLP-1 Receptor Agonist-Associated Colonic Ischemia
Ramrakhiani, H., Roorda, A. K., Tran, T., Shetler, K. P., & Triadafilopoulos, G. (2025) · Digestive Diseases and Sciences · doi:10.1007/s10620-025-08984-2 · Cited by 2
“Diarrhea, observed in 10–20% of cases, is likely mediated by altered gut motility and hormone secretion, whereas constipation, occurring in approximately 20% of patients, is a consequence of reduced intestinal motility [5, 7].”
Goldberg, M., Blevins, J. E., Wolden‐Hanson, T., Elfers, C., Chichura, K. S., Ashlaw, E. F., den Hartigh, L. J., Roth, C. L., & Doyle, R. P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073032 · Cited by 2
“While these compounds evoke profound weight loss in the absence of bariatric surgery, they are still associated with a number of mild to moderate adverse gastrointestinal side effects, namely diarrhea, nausea, vomiting, and/or abdominal pain [11].”
InfluentialAwad, A. A., Abouelmagd, A. A., Mohammed, F., Elettreby, A. M., Marey, M. M., Aldemerdash, M. A., Soliman, S. M., Belal, M. M., & Abosheaishaa, H. M. (2025) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2025.2480512 · Cited by 4
Onboarding obesity management in cardiovascular care: A cardiologist's guide to latest advances
Schiele, F., Diévart, F., Jacobi, D., Angoulvant, D., Czernichow, S., Puymirat, É., Sabouret, P. F., & Aboyans, V. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.100987 · Cited by 2
“…which included patients with overweight and at least one weight-related complication or obesity without T2DM, tirzepatide was associated with a decrease in body weight of 15 %, 19.5 %, and 20.9 % at a dose of 5 mg, 10 mg, and 15 mg, respectively, from baseline to week 72 compared to placebo [22].”
InfluentialEvaluating the Impact of Tirzepatide on Clinical Outcomes in Patients With Heart Failure
Malik, M. H. B. A., Khan, N. N., Chowdhari, M. J., Rafiq, M. K., Ali, M., Sadia, L. N. U., Ramzan, H. S., Ahmed, M. M., & Khatoon, F. (2025) · Cureus · doi:10.7759/cureus.82118 · Cited by 6
“This is in line with previous literature [3,4,14,15].”
Medikamentöse Adipositastherapie in Deutschland
Blüher, M. (2025) · Die Innere Medizin · doi:10.1007/s00108-025-01897-2 · Cited by 4
Design of potent and proteolytically stable double biaryl-stapled GLP-1R/GIPR peptide dual agonists
Yang, Y., & Lin, Q. (2025) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2025.118215 · Cited by 2
Al-Qudah, A.-A., Al‐Hanaktah, M., & Albadaineh, R. (2025) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.16296 · Cited by 3
“21,22 Recent evidence highlights the broader metabolic benefits of GLP-1 receptor agonists, including favorable effects on hepatic steatosis and lipid profiles, making them an emerging treatment option for PCOS patients with prominent metabolic features.”
InfluentialImpact of glucagon-like peptide-1 receptor agonists on hypertension management: a narrative review
Oliveira-Gomes, D. D., Pingili, A., Inglis, S. S., Mandras, S. A., Loro-Ferrer, J. F., & daSilva‐deAbreu, A. (2025) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001225 · Cited by 2
“…once weekly (doses ranging from 5 to 15 mg) experienced a significant reduction in SBP of (cid:4) 6.2mmHg (95% CI (cid:4) 7.7, (cid:4) 4.8) and a reduction in DBP of (cid:4) 4.0mmHg (95% CI (cid:4) 4.9, (cid:4) 3.1) after 72 weeks, compared to the placebo group in a pooled analysis [46].”
InfluentialFaghfouri, A. H., Musazadeh, V., Mokari‐Yamchi, A., Faramarzi, F., Pam, P., Shekari, S., Mahmoudzadeh, M., & Gheibi, S. (2025) · Obesity Reviews · doi:10.1111/obr.13946 · Cited by 3
Emerging Strategies for Drug-Based Cancer Risk Reduction
Daca-Álvarez, M., Brunori, A., Carbone, A., Carbonell, C., Tangen, C. M., Unger, J. M., Lucia, M. S., Oliva, M., Censi, A. D., Brenner, D. R., et al. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-473708 · Cited by 3
Incretins for management of obesity and obstructive sleep apnea
Hu, X., Yee, B. J., Phillips, C. L., Chapman, J. L., & Grunstein, R. R. (2025) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2025.2513516 · Cited by 2
“The efficacy of tirzepatide was demonstrated in the SURMOUNT-1 study which randomized participants to placebo or varying doses of tirzepatide over 72 weeks [61].”
InfluentialKammaripalle, T. K. C., Giordano, J., Rana, H., Gade, A. R., & Reddy, S. (2025) · Cureus · doi:10.7759/cureus.85366 · Cited by 4
Lindahl, M., Mortensen, G. L., Larsen, M., Thrysøe, P., Bach, C. N., Geert-Jørgensen, A., Mathiesen, T. W., Gulstad, K. N., Noer, B. R., Fogstrup, I. H., et al. (2025) · European Journal of Physiotherapy · doi:10.1080/21679169.2025.2519345 · Cited by 2
“…and maintain a physically active lifestyle. counselling about physical activity and diet was part of the studies examining the effects of WRD [4,5,9], and lifestyle counselling is recommended when the medication is prescribed by general practitioners [10]. however, that task can be challenging…”
Glucagon-like Peptide-1 Receptor Agonists: A New Frontier in Treating Alcohol Use Disorder
Oesterle, T., & Ho, M. (2025) · Brain Sciences · doi:10.3390/brainsci15070702 · Cited by 6
Anesten, F., Zlatkovic, J., Ohlsson, C., Löken, L. S., Hägg, D. A., & Jansson, J. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.07.009 · Cited by 2
“The combination of GLP-1-and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, such as Tirzepatide, causes approximately 15 – 20 % weight loss within 1 – 2 years (Jastreboff et al., 2022).”
Sardà, H., Genua, I., & Miñambres, I. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2025.106951 · Cited by 4
Emerging concepts in obesity management: focus on glucagon receptor agonist combinations
Anderson, S. L. (2025) · Drugs in Context · doi:10.7573/dic.2025-4-8 · Cited by 4
Challenges in Modelling the Cost Effectiveness of Pharmacotherapies for Obesity
Pennington, B., Cummins, E., Chandler, A., & Fotheringham, J. (2025) · PharmacoEconomics · doi:10.1007/s40273-025-01520-0 · Cited by 4
“The primary endpoints of clinical trials for anti-obesity agents relate to weight loss, and secondary endpoints include blood pressure, glycated haemoglobin (HbA1c), and lipid levels [17, 18].”
Zhang, J., Xu, H., Dong, Y., Feng, J., & Li, R. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118024 · Cited by 2
EndoBridge 2024: pearls and highlights
Yıldız, B. O., Armeni, E., Balodimou, C., Biondi, B., Ciudin, A., Frühbeck, G., Fuleihan, G. E., Geer, E. B., Gillard, P., Gordon, C. M., et al. (2025) · HORMONES · doi:10.1007/s42000-025-00708-5 · Cited by 4
“These rapid advances, which are enabling the use of personalized medicine for the treatment of certain rare causes of obesity and effective treatment for many others, are now approaching the efficacy observed with surgical approaches [77–81].”
Effects of Weight-lowering Medications in People With Obesity and Rheumatic Diseases
Karacabeyli, D., & Lacaille, D. V. (2025) · Current Treatment Options in Rheumatology · doi:10.1007/s40674-025-00232-y · Cited by 3
Yskout, M., Steenackers, N., Hoste, J., Pazmiño, S., Simoens, C., Mattelaer, N., Deleus, E., Lannoo, M., Mertens, A. C., der Schueren, B. V., et al. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01870-x · Cited by 5
METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE: UPDATE
Dezan, M. G. F., de Oliveira, C. P. M. S., & Cotrim, H. P. (2025) · Arquivos de Gastroenterologia · doi:10.1590/s0004-2803.24612025-117 · Cited by 4
Cardiovascular effects of semaglutide and tirzepatide and their potential for cardioprevention
Cherkashin, D. V., Салухов, В. В., & Khalimov, Y. S. (2025) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2025-323 · Cited by 2
Mi, L., Li, T., Xiang, X., Zhou, Y., Xiong, N., Chen, Y., Chen, J., Shang, S., Chen, S., Cheung, W. W., et al. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.09.009 · Cited by 2
“Clinical trials have shown that TZP at 15 mg per week promoted dramatic weight loss of about 20 % in 56.7 % of patients with obesity [22].”
InfluentialGLP-1 and GIP agonists in diabetes and obesity and the rise of dyspepsia
Masulli, M., Tack, J. F., Esposito, G., & Sarnelli, G. (2025) · Internal and Emergency Medicine · doi:10.1007/s11739-025-04117-9 · Cited by 3
“The widespread use of glucagon-like peptide-1 (GLP-1) receptor agonists and, more recently, dual agonists targeting both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP), such as tirzepatide, has significantly enhanced therapeutic strategies for type 2 diabetes and obesity [1–5].”
Illiano, J., Green, C. L., Chao, A., Zhu, G., Lopez, L., Schaepkens, O., Jang, C., Lamming, D. W., & Harris, D. A. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102471 · Cited by 6
Khunti, K., Mourer, A., Capucci, S., Wilkinson, L., Andersen, K. K., Tahrani, A. A., & Morgen, C. S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70446 · Cited by 6
“25,36,37 40 Reduced incidence of hospitalisations has also been noted with pharmacological intervention-assisted weight loss, although not with metabolic surgery.”
Advent of tirzepatide: boon for diabetic and obese?
Bhusal, A. (2023) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000000173 · Cited by 2
“Obesity affecting approximately 600 million people, is the most prevalent chronic disease worldwide([3]).”
BackgroundEffet du bi-agoniste GLP-1/GIP sur le poids, le tissu adipeux et les lipides
Vergès, B. L. (2023) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2023.06.004 · Cited by 3
Ordinaries 12: Return to the Pleistocene
Burnham, T. C., & Phelan, J. (2023) · Journal of Bioeconomics · doi:10.1007/s10818-023-09336-8 · Cited by 2
“After 18 months of Mounjoro use, more than half of patients lost at least 20% of their body weight (Jastreboff et al., 2022; Syed, 2022).”
BackgroundMethodMultiple new therapeutic options for the treatment of obesity
Umińska, J. M. (2023) · Medical Research Journal · doi:10.5603/mrj.97463 · Cited by 2
Metabolism and Target Organ Damage
Fearon, N. M., & Pournaras, D. J. (2022) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2022.12 · Cited by 3
Fat – pharmacological therapies
Bain, S. C. (2022) · British Journal of Diabetes · doi:10.15277/bjd.2022.367 · Cited by 2
GLP-1 agonists in treatment of obesity
ORŁOWSKI, W., MERKISZ, K., Zdun, S., Walczak, K., Walczak, P., Nemeczek, S., Grzybowski, J., Marciniak, A., JASKUŁA, K., & Grzywna, N. (2023) · Journal of Education Health and Sport · doi:10.12775/jehs.2023.13.02.033 · Cited by 2
A „másik” inkretin – a glükózdependens insulinotrop polipeptid terápiás újrafelfedezése
Winkler, G., Kis, J. T., & Schandl, L. (2023) · Orvosi Hetilap · doi:10.1556/650.2023.32710 · Cited by 5
Review of upcoming and currently available anti-obesity drugs in Europe
Gryszkiewicz, P., Szydło, J., Starownik, J., Wędrychowski, J., & Zabielska, B. A. (2023) · Journal of Education Health and Sport · doi:10.12775/jehs.2023.30.01.005 · Cited by 4
Obesity-related hypertension: Implications for advanced nursing practice
Benenson, I., & Prado, K. (2023) · The Nurse Practitioner · doi:10.1097/01.npr.0000000000000055 · Cited by 2
The prospective record-breaking obesity drug tirzepatide raises concerns about affordability
Seetharaman, R., Pandit, S., & Joshi, S. S. (2023) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2023-0129 · Cited by 2
Martínez, P. P., Gómez‐Huelgas, R., Escribano, P. P. C., Arévalo‐Lorido, J. C., Soto, M. I. P., & Carretero‐Gómez, J. (2023) · Revista Clínica Española · doi:10.1016/j.rce.2023.05.007 · Cited by 2
Calderon, R. M., Golczak, M., Paik, J., & Blaner, W. S. (2023) · Journal of Nutrition · doi:10.1016/j.tjnut.2023.08.030 · Cited by 2
Early effect of exenatide treatment on atherogenicity in patients with type 2 diabetes mellitus
Menekşe, B., & Batman, A. (2023) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-023-01233-0 · Cited by 2
“In addition, a new glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist drug called tirzepatid has been used in recent years [3, 4].”
Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction
Khan, S. S., & Meyer, M. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2023.08.012 · Cited by 2
Al‐Horani, R. A., Aliter, K. F., & Aliter, H. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998276832231124170324 · Cited by 5
Newer Outpatient Diabetes Therapies and Technologies
Kamal, N., Lee, K., & Aleppo, G. (2024) · Medical Clinics of North America · doi:10.1016/j.mcna.2024.03.002 · Cited by 2
Wee, C. C., Arbaje, A. I., Bering, H., Blount, L. G., Joseph, J. J., Kahan, S. I., Apovian, C. M., & White-Faines, A. (2025) · Annals of Internal Medicine · doi:10.7326/annals-25-00675 · Cited by 3
Update in Outpatient General Internal Medicine: Practice-Changing Evidence Published in 2022
Huber, J. M., Wieland, M. L., Bornstein, S. L., Mauck, K. F., Szostek, J. H., Post, J. A., & Wingo, M. T. (2023) · The American Journal of Medicine · doi:10.1016/j.amjmed.2023.05.014 · Cited by 2
Handley, D., Almansoori, S., Sato, M. S., Amin, H. A., Alsters, S., Chahal, H., Purkayastha, S., Murphy, K. G., van Haelst, M. M., le Roux, C. W., et al. (2023) · medRxiv · doi:10.1101/2023.05.22.23290347 · Cited by 1
Hall, K. D. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.05.565699 · Cited by 2
GLP-1R agonists activate human hypothalamic neuronsPreprint
Mazzaferro, S., Chen, H. C., Cahn, O., Yang, A., Shepilov, D., Seah, E., Chen, J., Jawahar, B., Alcaino, C., Macarelli, V., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.02.587825 · Cited by 4
Park, C. J., Lee, A. T., & Ou, S. I. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-02514 · Cited by 2
Anti-Obesity Medication Considerations in Older AdultsPreprint
Williams, L. F., & Purcell, M. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5389209 · Cited by 2
Schmickl, C. N., Tripipitsiriwat, A., Mokhlesi, B., et al. (2025) · medRxiv · doi:10.1101/2025.10.02.25337176 · Cited by 2
“Furthermore, in routine practice, tirzepatide adherence may fall short of the > 80% in the SURMOUNT trials [24 , 25 ].”
InfluentialSun, X., Yin, Y., Song, M., Droz, B. A., LIN, Y., Beaty, K. N., Zhou, B., Roh, H. C., Wilson, J. M., Cain, P., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.18.695152 · Cited by 2
Kang, D., & Choi, D. (2026) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2025.277 · Cited by 1
“It is administered subcutaneously once weekly, beginning at 2.5 mg and titrated up to a maximum of 15 mg [23,24].”
InfluentialPrecision Bariatric/Metabolic Medicine and Surgery
Genser, L., Thabut, D., & Aron‐Wisnewsky, J. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12051909 · Cited by 1
“dose-dependent weight loss (mean 22% weight loss), and this treatment will most likely become available in the future [29].”
BackgroundLes médicaments de l’obésité : état actuel et futures avancées
Lassen, P. B., & Aron‐Wisnewsky, J. (2023) · Cahiers de Nutrition et de Diététique · doi:10.1016/j.cnd.2023.04.005 · Cited by 3
The sun is rising on a new era of pharmacotherapy for obesity: some words of caution
Benotti, P. N., & Bistrian, B. R. (2023) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2023.05.023 · Cited by 1
Lifestyle Modification for the Management of Psoriatic Arthritis
deBoisblanc, C., Hynes, M., & Mbuyi, N. (2023) · American Journal of Lifestyle Medicine · doi:10.1177/15598276231197621 · Cited by 3
“81 Given the evidence for weight loss and its effects on PsA, these drugs may offer patients with PsA another way to achieve symptom control.”
Tirzepatide maintained significant weight loss when treatment was continued in a follow‐up study
IDRIS, I. R. (2023) · Diabetes Obesity and Metabolism Now · doi:10.1002/doi2.79 · Cited by 1
SURMOUNTing body weight barriers in type 2 diabetes
Novikoff, A., & Müller, T. D. (2023) · Med · doi:10.1016/j.medj.2023.11.007 · Cited by 1
Appetite and its Regulation: Are there Palatable Interventions for Heart Failure?
Lee, M. M. Y., Lean, M. E. J., Sattar, N. A., & Petrie, M. C. (2023) · Current Heart Failure Reports · doi:10.1007/s11897-023-00637-7 · Cited by 5
“The new GLP-1 receptor agonists, GIP and glucagon receptor agonists, potently and sustainably reduce appetite, and, taken together with dietary advice, can produce substantial, life-changing, weight loss approaching that achieved by surgery [7, 8].”
Background
Metadata
- Authors
- Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A.
- Affiliations
- Eli Lilly (United States) (US)
- From the Section of Endocrinology and Metabolism, Department of Medicine, and the Section of Pediatric Endocrinology, Department of Pediatrics, Yale University School of Medicine, New Haven, CT (A.M.J.); the Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine, New York (L.J.A.); Eli Lilly, Indianapolis (N.N.A., S.Z., B.L., M.C.B., A.S.); McMaster University, Hamilton, and York University and Wharton Weight Management Clinic, Toronto — all in Ontario, Canada (S.W.); Intend Research, Norman, OK (L.C.); Centro Paulista De Investigação Clínica (Cepic), Sao Paulo (B.A.); and Tokyo-Eki Center-Building Clinic, Tokyo (A.K.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-07-21
- Volume
- 387
- Issue
- 3
- Pages
- 205-216
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4281934192
- Semantic Scholar
- 3fb03384cc726ebd9d08c76482e6edf35502d0c7
- Cited by
- 3,838
- References
- 28
- Citations by year
- 2026: 1279 · 2025: 1067 · 2024: 776 · 2023: 562 · 2022: 149
- FWCI
- 382.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- tirzepatide, obesity, weight loss, GLP-1 receptor agonists, GIP receptor agonist, glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, dose escalation, body mass index, weight-related comorbidities, treatment discontinuation, treatment-emergent adverse events, drug safety, subcutaneous administration
- MeSH terms
- Tirzepatide, Adult, Dose-Response Relationship, Drug, Double-Blind Method, Glucagon-Like Peptides, Gastric Inhibitory Polypeptide, Humans, Injections, Subcutaneous, Obesity, Weight Loss, Treatment Outcome, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.